Health Care • Misc Health and Biotechnology Services
$193.31 ▲ +9.38
(+5.10%)
MKT CAP: $12.33B • VOL: 2.08M
52W L $101 52W H $247
DVA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $13.64B | $12.82B | $12.14B |
| YoY Revenue Growth % | +6.5% | +5.6% | — |
| Gross Profit | $6.00B | $5.64B | $5.34B |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $2.04B | $2.09B | $1.60B |
| Operating Margin % | 15.0% | 16.3% | 13.2% |
| Net Income (GAAP) | $1.08B | $1.25B | $957.0M |
| EBITDA (Normalized) | $2.50B | $2.53B | $2.04B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.89B | $2.02B | $2.06B |
| Capital Expenditures (CapEx) | $575.9M | $555.4M | $546.3M |
| Free Cash Flow (FCF) | $1.31B | $1.47B | $1.51B |
| FCF Margin % | 9.6% | 11.4% | 12.5% |
| Return on Invested Capital (ROIC %) | 26.8% | 26.8% | 14.4% |
| Cash & Short-Term Equivalents | $676.4M | $794.9M | $1.60B |
| Total Debt (Short + Long Term) | $7.34B | $6.84B | $3.41B |
| Total Stockholders' Equity | -$651.1M | $121.1M | $6.99B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DVA.